QNRX vs VRAX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VRAX Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Virax Biolabs Group Limited Ordinary Shares (VRAX) driven by superior Growth & Margin, Momentum & Technical while QNRX counters with relative strength in Valuation. Fundamentally, QNRX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus VRAX at N/M Forward P/E and -51515.2% operating margin (+684.9% YoY). In options structure, QNRX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against VRAX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | QNRX | VRAX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $16.1M | $470,745 | Larger Scale | QNRX |
| Trailing P/E Ratio Valuation | 7.6x | N/M | Lower Multiple | QNRX |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +684.9% | Higher Growth | VRAX |
| Operating Margin (TTM) Profitability | 0.0% | -51515.2% | Higher Margin | QNRX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -142.6% | -78.6% | Higher ROE | VRAX |
| 52-Week Range Position Momentum | 0% ($3โ$24) | 2% ($0โ$13) | Stronger Trend | VRAX |
| Beta / 30D Volatility Risk Regime | 1.34ฮฒ ยท 74% Vol | -8.20ฮฒ ยท 162% Vol | Lower Realized Risk | QNRX |
| Unified Institutional Score Composite Signal | 46.1 / 100 (HOLD) | 46.5 / 100 (HOLD) | Higher Composite | VRAX |